The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...
Zacks Investment Research on MSN
Merck indicates better growth visibility in post-Keytruda LOE period
Merck MRK announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both ...
A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...
Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom. This 470 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results